Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2008
10/23/2008US20080262004 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-pyrrolo[2,3-b]pyridine; to treat autoimmune disorders like rheumatoid arthritis, glomerulonephritis, neoplasms; antifibrotic agents
10/23/2008US20080262001 Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
10/23/2008US20080261998 Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
10/23/2008US20080261989 Quinoxaline Inhibitors of the Hedgehog Signalling
10/23/2008US20080261988 IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
10/23/2008US20080261985 treating a disorder characterized by the overexpression of iNOS or COX-2 genes; rheumatoid arthritis, inflammatory bowel disease, lupus, multiple sclerosis, or psoriasis; cancer
10/23/2008US20080261982 autoimmune disease and liver cirrhosis; useful for killing hyperproliferating cells
10/23/2008US20080261980 4-{5-[3-(3,4,5-trimethoxybenzyl)-4-oxo-2-thioxo-thiazolidine-5-ylidenemethyl]-furan-2-yl}benzoic acid; inhibition of the interaction between HIF-1 alpha and p300
10/23/2008US20080261978 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea
10/23/2008US20080261976 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
10/23/2008US20080261975 Including Itk kinase; 1-[2-[4-(3-Dimethylamino-propoxy)-phenyl]-4-methyl-5-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-2-methyl-propan-2-ol; inflammation, immunological and allergic disorders
10/23/2008US20080261971 Novel Heterocyclic Nf-Kb Inhibitors
10/23/2008US20080261969 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them
10/23/2008US20080261965 Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases
10/23/2008US20080261963 antibiotics, fungicides, viricides; treating microbial infections; fused rings based on 4-oxo-4H-pyrido[3,2,1-kl]benzo[g]-phenoxazine for example; Tumor suppression agents with reduced side effects; anticancer
10/23/2008US20080261961 Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases
10/23/2008US20080261960 Photosensitizers for photodynamic therapy; killing tissue, cells; anticancer agents
10/23/2008US20080261956 Substituted Phenols as Active Agents Inhibiting Vegf Production
10/23/2008US20080261943 Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use
10/23/2008US20080261935 Treating pancreatic cancer by administering cardenolide uscharin extracted from Calotropis procera plants
10/23/2008US20080261933 Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
10/23/2008US20080261929 Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
10/23/2008US20080261925 Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by administering a 19-nor containing vitamin d analog with or without a retinoid
10/23/2008US20080261923 Inhibitory activity against Pin1; inhibit peptidyl-prolyl isomerase activity of Pin1; inhibits growth of cancer cells; Ac-Phe-Tyr-phosphoSer- pseudo amide -Pro-Arg-NH2; Fmoc-bis(POM) phosphoSer- pseudo amide -Pro-2-aminoethyl-(3-indole) and their Phospho-(D)-serine stereoisomers
10/23/2008US20080261921 Fused ring heterocycle kinase modulators
10/23/2008US20080261919 Camptothecin-analog with a novel, "flipped" lactone-stable, E-ring and methods for making and using same
10/23/2008US20080261917 Prodrug; novel series of compounds which inhibit the MDM2-p53 interaction and have in vitro activity exerting an anti-tumour effect; cancer
10/23/2008US20080261916 Nutraceutical; plant extracts and oils; fructose, glucose, starch, inulin, oligofructoses, fructo-oligosaccharides, lactulose, galactomannan, indigestible polydextrose, acemannan, various gums, indigestible dextrin, phytosterol, phytostanol, vitamins, minerals; symptoms of chronic intestinal inflammation
10/23/2008US20080261913 Compounds and pharmaceutical compositions for the treatment of liver disorders
10/23/2008US20080261912 For treatment of endocrine-regulated tumors, for example, breast, prostate, ovarian and colon cancers
10/23/2008US20080261911 Uses of diphenyl/diphenylamine carboxylic acids
10/23/2008US20080261908 Adverse prognostic markers estrogen receptor, progesterone receptor expression, positive lymph node metastasis, high proliferative index, detectable p53 expression; identify breast cancer-specific signature of miRNAs differentially-expressed in breast cancer cells relative to normal control cells
10/23/2008US20080261907 siRNA blocks expression of sphingosine kinase, potentiates effect of radiation in cancer cells of breast, prostate, colorectal, lung, bladder, head and neck, intestine, ovarian, skin; reduces amount of radiation needed to decrease cancer cell viability, tumor size in vivo
10/23/2008US20080261903 Isolated polynucleotide encoding a Regulated in chronic obstructive pulmonary disease Kinase polypeptide; host cell; hybridization; screening; prediction, diagnosis; prognosis; chronic obstructive pulmonary disease, asthma, cancer, diseases of defective cell signaling
10/23/2008US20080261898 Composition and method for cancer treatment and prevention
10/23/2008US20080261892 Angiogenesis; neovascularization; lyophilization; kits
10/23/2008US20080261883 Runx3 gene showing anti-tumor activity and use thereof
10/23/2008US20080261877 Albumin Fusion Proteins
10/23/2008US20080261874 Point mutations; single or double alternation of tyrosine and aspartate residues; carcinoma; AIDS; gene therapy
10/23/2008US20080261871 Y2/Y4 Selective Receptor Agonists for Therapeutic Interventions
10/23/2008US20080261870 Use of the Pro-Peptide Domain of Lysyl Oxidase as a Therapeutic Agent
10/23/2008US20080261867 Soluble inhibitors of vascular endothelial growth factor and use thereof
10/23/2008US20080261865 Oxidized Lipids and Uses Thereof in the Treatment of Inflammatory Diseases and Disorders
10/23/2008US20080261862 Integrin mediates proliferative signal provided by CD23 to pre-B cells; immobilized rodent cells; drug screening; anticancer agents; antiinflammatory agents
10/23/2008US20080261303 Method and medicament for inhibiting the expression of a given gene
10/23/2008US20080261228 Using prostate cancer antigen (PCA) expression as evaluative tool in diagnosis/prognosis of cancer
10/23/2008US20080260857 Water and succinic acid; administered orally or parenterally
10/23/2008US20080260838 Pulmonary delivery of GLP in combination with diketopiperazine that is stable both in vitro and in vivo; diabetes, cancers, and obesity
10/23/2008US20080260834 Localized delivery of 1,25 D3 directly to target area using biodegradable polymeric matrices maximizes the efficacy of drug while minimizing systemic exposure and toxicity; inhibit tumor viability or proliferation
10/23/2008US20080260829 Bone morphogenic proteins (bmp); cell adhesion modulating agent; peptidomimetics of cyclic peptides comprising classical cadherin cell adhesion recognition (CAR) sequences; modulate cell adhesion and improve drug delivery
10/23/2008US20080260821 Berry Preparations and Extracts
10/23/2008US20080260820 Providing effective gastrointestinal tract drug delivery; therapeutic protein having primary amino acid sequence modification
10/23/2008US20080260812 Therapeutic Medicine Containing Monoclonal Antibody Against Folate Receptor Beta (Fr-Beta)
10/23/2008US20080260790 Increase acoustic deposits at target using plasmid; nanostructure biocompatible solid; plasmid intensifier comprises a core material encapsulated by membrane in aqueous solution
10/23/2008US20080260780 Materials and methods relating to improved vaccination strategies
10/23/2008US20080260772 Food; antiproliferation agents; extraction from fruit using heated water; dialysis; chromatography
10/23/2008US20080260770 Use of Tellurium Compounds as Adjuvants
10/23/2008US20080260760 Nucleotide sequences coding prostate-specific antigen-derived peptide for use as vaccine inntreatment of urogenital cell proliferative disorders
10/23/2008US20080260758 Cell which expresses granulocyte colony stimulating factor and is deficient in major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which stimulates immune response to cancer
10/23/2008US20080260756 Peptide Inhibitors of iASPP
10/23/2008US20080260749 Novel Tetrahydropyridothiophenes
10/23/2008US20080260748 Desmocollin 2 (DSC2) specific immunoglobulin for use in prevention and treatment of cell proliferative disorders
10/23/2008US20080260747 Adhesion interaction protein (CD-84) specific immunoglobulin for use in the treatment of cell proliferative disorders of the blood
10/23/2008US20080260746 Erythropoietin polypeptide for use in treatment and prevention of viral, skin, nervous system, autoimmune, cardiovascular, kidney, cell proliferative and cardiovascular disorders
10/23/2008US20080260745 Targeted identification of immunogenic peptides
10/23/2008US20080260742 Preventives/Remedies for Cancer
10/23/2008US20080260741 Preventive and/or Therapeutic Agent for Cancer
10/23/2008US20080260735 Glycoprotein-340 for use in targeted destruction of cancer tissues; immunotherapy
10/23/2008US20080260733 Humanized collagen antibodies and related methods
10/23/2008US20080260729 Using RNA interference and/or endothelial growth factor specific immunoglobulins to target, treat and prevent cell proliferative disorsders
10/23/2008US20080260725 Tag and target delivery system
10/23/2008US20080260721 Nucleotide sequences coding regulatory-associated protein of mTOR (Raptor) protein for use in identifying modulators for prevention and treatment of cancer and diabetes
10/23/2008US20080260720 Systems and Methods for Inhibiting Metastasis
10/23/2008US20080260711 Detoxifizyme with Activity of Transforming Aflatoxin and the Gene Encodes Thereof
10/23/2008US20080260709 Probiotic yeast broth for reducing blood or hepatic cholesterol level and preventing and/or treating cell proliferative and atherogenic disorders
10/23/2008US20080260701 Cytokine induced killer cell populations for use in treatment of cell proliferative disordersl; tissue engineering and repair; tissue targeted therapy
10/23/2008US20080260695 Nutrient broth comlprising fermented soy extract, oligomeric proanthocyanidin, epigallocatechin gallate, spirulina, curcumin and antrodia camphorata for use as antitumor therapeutic
10/23/2008US20080260688 Imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea
10/23/2008US20080260687 Identifying modulators which interfere with interleukin-6 and interleukin-6 receptor binding; antitumor agents; treating cell proliferative disorders
10/23/2008US20080260685 Prodrugs of cc-1065 analogs
10/23/2008US20080260638 Receptor(sstr2)-selective somatostatin antagonists
10/23/2008US20080260635 Mediation of cytotoxicity of tumor cells; using cancer disease modifying antibodies and drugs; initiating cytotoxic response; binding analysis
10/23/2008DE102007016046A1 Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung Process for the preparation of epothilone derivatives by selective catalytic epoxidation
10/23/2008CA2684211A1 Hydroquinone ansamycin formulations
10/23/2008CA2684056A1 Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
10/23/2008CA2684008A1 Diphenyl-dihydro-imidazopyridinones
10/23/2008CA2683973A1 Sparc and methods of use thereof
10/23/2008CA2683890A1 Methods and compositions for contributing to the treatment of cancers
10/23/2008CA2683820A1 Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
10/23/2008CA2683785A1 Aminopyrimidines useful as kinase inhibitors
10/23/2008CA2683784A1 Pyrido[2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
10/23/2008CA2683624A1 Pharmaceutical compounds
10/23/2008CA2683622A1 2-morpholin-4-yl-pyrimidines as pi3k inhibitors
10/23/2008CA2683619A1 Pharmaceutical compounds
10/23/2008CA2683559A1 Methods for treating cancer resistant to erbb therapeutics
10/23/2008CA2683454A1 Tem8 peptides and vaccines comprising the same
10/23/2008CA2683444A1 Administration of carboline derivatives useful in the treatment of cancer and other diseases
10/23/2008CA2683314A1 Isolated nucleic acid molecules corresponding to micro rna 145 (mirna-145) and their use in treating colon cancer
10/23/2008CA2683089A1 Benzimidazole derivatives and imidazopyridine derivatives with glucose lowering effect
10/23/2008CA2682733A1 Axl kinase inhibitors
1 ... 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 ... 2211